Liminatus Pharma, Inc. Class A Common Stock
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LIMN research report →
Price Chart
About the company
Liminatus Pharma, Inc. is an immuno-oncology firm, currently in its clinical development phase, dedicated to pioneering new treatments for cancer. The company's headquarters are located in La Palma, California.
- CEO
- Chris Kim
- IPO
- 2025
- Employees
- 1
- HQ
- Cerritos, CA, US
Get TickerSpark's AI analysis on LIMN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $3.77M
- P/E
- -0.12
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 4.44
- EV/EBITDA
- -0.18
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 443.60%
- ROIC
- -225.12%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-2,967,812
- Net Income
- $-10,206,517-251.4%
- EPS
- $-21.50-7.5%
- OCF Growth
- -220.7%
- FCF Growth
- -221.2%
- Beta
- 0.75
- RSI (14)
- 45
No earnings-call transcripts are available for LIMN yet.
- Free Float
- 35.3%
- Shares Outstanding
- 1.34M
- Float Shares
- 473.59K
of shares held by institutions
15 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Cygnus Capital Advisors, LLC | 329.33K | ▼ 20.67K |
| Vanguard Group Inc | 73.42K | 0 |
| Citadel Advisors LLC | 56.09K | ▼ 621.43K |
| Vanguard Personalized Indexing Management, LLC | 13.15K | ▼ 21.56K |
| Tower Research Capital LLC (Trc) | 7.09K | ▼ 474 |
Held by 7 ETFs
Biggest fund positions in LIMN by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 2, 26 | Valetudo Therapeutics LLC | other | 3,448,926 |
| Jun 24, 26 | Valetudo Therapeutics LLC | other | 4,373,603 |
| Jun 24, 26 | Ewon Comfortech Co., Ltd. | other | 0 |
| Apr 30, 25 | Iris Acquisition Holdings LLC | other | 0 |
| Jul 10, 25 | Lemons II Philip Wayne | other | 0 |
| Jul 10, 25 | Baek Richard JaiHwan | other | 0 |
| Apr 30, 25 | KH Feelux Co., Ltd | other | 0 |
| Apr 30, 25 | Valetudo Therapeutics LLC | other | 0 |
| Apr 30, 25 | Lee Eun Sook | other | 0 |
| Apr 30, 25 | Baek Ji Yeon | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our LIMN coverage
Recent articles, reports, and earnings notes.
No research on LIMN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate LIMN report →